Psychiatry and Psychology [F] » Mental Disorders [F03] » Schizophrenia Spectrum and Other Psychotic Disorders » Schizophrenia
Description
A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. MeSH
Hierarchy View
Subtype Terms (5)
Schizophrenia, Catatonic
1 approved drug
Schizophrenia, Disorganized
2 approved drugs
Schizophrenia, Paranoid
10 drugs (7 approved, 3 experimental)
Schizophrenia, Treatment-Resistant
10 approved drugs
Approved Indicated Drugs (40)
Phase 4 Indicated Drugs (100)
Phase 3 Indicated Drugs (84)
Phase 2 Indicated Drugs (99)
Phase 1 Indicated Drugs (50)
Other Experimental Indicated Drugs (45)
Organization Involved with Phase 4 Indications (228)
All India Institute of Medical Sciences
Amanuel Mental Hospital, Addis Ababa, Ethiopia
American Legion of Iowa Foundation
American Psychiatric Association
Beer Yaakov and Ness Ziona Mental Health Center
Brain & Behavior Research Foundation
Brentwood Biomedical Research Institute
Case Western Reserve University
Central Institute of Psychiatry, Ranchi, India
Central Mental Clinic for Outpatients of Baku City
Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec
Centre de recherche Fernand-Seguin, Hôpital Louis-H. Lafontaine
Centro de Investigación Biomédica en Red (CIBER)
Collaborative Neuroscience Network
Daewoong Pharmaceutical Co. LTD.
Federal University of Rio Grande do Sul
Forensic Psychiatric Institute
Guangzhou Psychiatric Hospital
Hamilton Health Sciences Corporation
Handok Pharmaceuticals Co., Ltd.
Hospital Psiquiatrico Infantil Dr. Juan N. Navarro, Mexico
Huazhong University of Science and Technology
Icahn School of Medicine at Mount Sinai
International Schizophrenia Foundation
Michael J. Gill Mental Health Clinic
Moorgreen Hospital, Southampton
National Health and Medical Research Council, Australia
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of Mental Health and Neuro Sciences, India
National Institute of Mental Health (NIMH)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Institute on Drug Abuse (NIDA)
National Institutes of Health (NIH)
North Suffolk Mental Health Association
Palo Alto Veterans Institute for Research
Provincial Health Services Authority
Ram Manohar Lohia Insitute of Medical Sciences
Research Foundation for Mental Hygiene, Inc.
Sha'ar Menashe Mental Health Center
Standard Chem. & Pharm. Co., Ltd.
Stanley Medical Research Institute
State University of New York, Buffalo
State University of New York, Syracuse
Taichung Veterans General Hospital
Technical University of Munich
The Hospital Pharmcacy North Denmark Region, Denmark
The Ian Douglas Bebensee Foundation
The Massachusetts Mental Health Center
The University of Texas, Dallas
Universidad Nacional de Rosario
University of California, Davis
University of California, Irvine
University of California, Los Angeles
University of California, San Diego
University of California, San Francisco
University of Erlangen-Nuremberg
University of Illinois at Chicago
University of Medicine and Dentistry of New Jersey
University of Missouri, Kansas City
University of North Carolina at Chapel Hill
Veterans Medical Research Foundation
Wallace Kettering Neuroscience Institute
Washington University in St. Louis
Organization Involved with Phase 3 Indications (100)
Abarbanel Mental Health Center
Accutest Research Laboratories (I) Pvt. Ltd.
Clinic for Psychiatric Disorders
Clinic for Psychiatric Disorders, Dr Laza Lazarevic
Cognitive Research Corporation
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Corporation de Recherche en Neuropsycho Pharmacologie de Quebec
Desert Pacific Mental Illness Research, Education, and Clinical Center
Federal University of Health Science of Porto Alegre
Geestelijke gezondheidszorg voor mensen in Eindhoven en omgeving
Gottfried Wilhelm Leibniz Universität Hannover
Hannover Clinical Trial Center GmbH
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Johanne and Einar Eilertsen's research fund
Lviv National Medical University
National Cheng Kung University
National Research Foundation, Singapore
National University of Singapore
Norwegian University of Science and Technology
Scandinavian Society for Psychopharmacology
Shanghai Hotmed Sciences Co.,LTD
Shijiazhuang Pharma Group (CSPC)
Singapore Clinical Research Institute
Solveig and Johan P. Sommer's foundation
SyneuRx International (Taiwan) Corp
Taipei Veteran General hospital
University of Health Sciences Lahore
Organization Involved with Phase 2 Indications (113)
Amarantus BioScience Holdings, Inc.
Atlanta Center for Medical Research
Camden and Islington NHS Foundation Trust
Centers for Behavioral Health, LLC
Federal Neuro-Psychiatric Hospital, Yaba
Florida Clinical Research Center, LLC
Innovative Clinical Research, Inc.
Iran University of Medical Sciences
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Karwan e Hayat, Karachi, Pakistan
Katholieke Universiteit Leuven
Lancashire Teaching Hospitals NHS Foundation Trust
Laureate Institute for Brain Research
Methodist Cancer Center, Houston, Texas
North East London Foundation Trust
Northern Ontario School of Medicine
Pakistan Institute of Living and Learning
People's Liberation Army of China
Pharmaceutical Research Associates, Inc. (PRA)
Q.Mundewadi Ayurvedic Research & Charitable Trust
Salford Royal Foundation NHS Trust
Organization Involved with Phase 1 Indications (49)
Organization Involved with Other Experimental Indications (55)
Arthur P. Noyes Research Foundation
Canadian Psychiatric Research Foundation
Chhatrapati Sahuji Maharaj Medical University
Guang Dong Provincial Mental Health Institute
Jamaica Hospital Medical Center
Medical University of South Carolina
Mount Saint Vincent University
National Center for Research Resources (NCRR)
Postgraduate Institute of Medical Education and Research
Robert Wood Johnson Foundation
Royal Liverpool & Broadgreen University Hospitals NHS Truts
San Francisco Brain Research Institute
Hierarchy Tree View
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
